Swedish pharmaceutical company Newbury Pharmaceuticals AB (STO:NEWBRY) announced on Friday that it has received marketing authorisation for its generic version of pomalidomide in Denmark.

This approval marks the first step in a Scandinavian registration process, with approvals in Sweden and Norway expected to follow.

Pomalidomide Newbury in combination with bortezomib and dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior treatment regimen including lenalidomide.

The Scandinavian market for pomalidomide is estimated to be worth EUR37m annually.

Pomalidomide Newbury is a generic version of Imnovid.